Citigroup maintains Amgen at Neutral, raises price target to $465 from $405

What happened

Citigroup kept its Neutral rating on Amgen and raised its price target to $465 from $405, a 14.8% increase. The new target is roughly in line with Amgen’s Nov. 3 closing price of $461.26. Five recent analyst targets range from $410 to $536.

Confirmed

Global impact / market context

The higher target signals that Citigroup sees somewhat more value in Amgen than before, but its unchanged Neutral rating indicates it did not shift to a positive recommendation. Because the new target is close to the cited closing price, the update implies limited price difference on Citigroup’s measure.

Analyst inference

Recent analyst views are spread around the closing price: five targets range from $410 to $536, while Citigroup’s new $465 target sits near $461.26. That range shows differing assessments, but the article provides no evidence of resulting share-price movement or changes to Amgen’s business.

Analyst inference

What to watch

1. Compare later analyst updates with Citigroup’s $465 target and Neutral rating to see whether its view changes or remains near the cited closing price. Analyst inference
2. Track whether the five recent targets, currently spanning $410 to $536, shift or cluster more tightly as analysts publish further Amgen assessments. Analyst inference
3. Watch for company operating or financial updates that could explain a change in analyst targets; none are described in the supplied article. Analyst inference

Evidence

• Original source link unavailable